Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice

J Gen Virol. 2005 Jan;86(Pt 1):211-215. doi: 10.1099/vir.0.80530-0.


Severe acute respiratory syndrome coronavirus (SARS-CoV) has been identified as the aetiological agent of SARS. Thus, vaccination against SARS-CoV may represent an effective approach towards controlling SARS. The nucleocapsid (N) protein is thought to play a role in induction of cell-mediated immunity to SARS-CoV and thus it is important to characterize this protein. In the present study, an E1/partially E3-deleted, replication-defective human adenovirus 5 (Ad5) vector (Ad5-N-V) expressing the SARS-CoV N protein was constructed. The N protein, expressed in vitro by Ad5-N-V, was of the expected molecular mass of 50 kDa and was phosphorylated. Vaccination of C57BL/6 mice with Ad5-N-V generated potent SARS-CoV-specific humoral and T cell-mediated immune responses. These results show that Ad5-N-V may potentially be used as a SARS-CoV vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / genetics
  • Adenoviridae / metabolism
  • Animals
  • Antibodies, Viral / biosynthesis
  • Drug Evaluation, Preclinical
  • Female
  • Genetic Vectors
  • Mice
  • Mice, Inbred C57BL
  • Molecular Weight
  • Nucleocapsid Proteins / biosynthesis*
  • Nucleocapsid Proteins / genetics
  • Nucleocapsid Proteins / immunology
  • Phosphorylation
  • Recombinant Proteins / biosynthesis
  • SARS Virus / genetics*
  • SARS Virus / immunology
  • Severe Acute Respiratory Syndrome / immunology*
  • Severe Acute Respiratory Syndrome / prevention & control
  • T-Lymphocytes / immunology
  • Vaccination / methods*
  • Viral Vaccines / biosynthesis*
  • Viral Vaccines / genetics
  • Viral Vaccines / immunology


  • Antibodies, Viral
  • Nucleocapsid Proteins
  • Recombinant Proteins
  • Viral Vaccines